Abstract #1116

Assessing Response Heterogeneity following Radium 223 administration using Whole Body Diffusion Weighted MRI

Matthew David Blackledge^1,2, Dow Mu Koh^1,2, David J Collins^1,2, Erica Scurr², Julie Hughes², Martin O Leach^1,2, Chris Parker^1,3, and Nina Tunariu^1,2

¹Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, ²MRI Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, ³Urology Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Whole-Body Diffusion-Weighted-MRI is emerging as an imaging response biomarker in metastatic bone disease. Documentation of mixed therapeutic response is a key recommendation of the Prostate Cancer Working Group as recognition of coexistence of mixed response to therapy and clinical benefit. Radium-223 has shown efficacy in prostate cancer patients with symptomatic bone metastases. Monitoring Radium-223 therapy efficacy treatment is challenging, as Radium-223 administration can be associated with flare in pain, PSA and Bone Scan. These pilot data demonstrate that Radium-223 administration is associated with an increase in bone metastases ADC values together with a mixed response pattern.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.